GlassScriptPhysician profile
Dipali Nemade
NPI 1679008387
$38,253.38
in general payments reported to CMS, 2019-2025
39 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.40 · 2022: $319 · 2023: $3,110 · 2024: $14K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $7,350 · Food and Beverage: $6,887 · Travel and Lodging: $3,750 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,900.00 |
| Consulting Fee | $7,350.00 |
| Food and Beverage | $6,887.25 |
| Travel and Lodging | $3,749.62 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $32,005.22 | 2022-2025 | Briviact, Fintepla, Nayzilam |
| Neuropace, INC. | $1,310.06 | 2023-2025 | |
| Medtronic, INC. | $1,161.37 | 2025 | Visualase |
| Abbvie INC. | $750.51 | 2023-2025 | |
| Neurelis, INC. | $381.51 | 2023-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $322.56 | 2022-2025 | Nuplazid, Daybue |
| Sk Life Science, INC. | $319.20 | 2022-2024 | Xcopri |
| Catalyst Pharmaceuticals, INC. | $285.20 | 2023-2025 | Fycompa |
| Biogen, INC. | $173.49 | 2023-2025 | Spinraza, Skyclarys |
| Jazz Pharmaceuticals INC. | $169.21 | 2023-2024 | |
| Pfizer INC. | $134.94 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.15 | 2023-2025 | Hyqvia, Gammagard |
| Alexion Pharmaceuticals, INC. | $106.92 | 2024-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $92.69 | 2022-2024 | Austedo Xr |
| Lilly USA, LLC | $87.78 | 2023-2025 | Emgality, Reyvow |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $81.02 | 2024-2025 | Uplizna |
| Genentech USA, INC. | $71.56 | 2024-2025 | Ocrevus Zunovo, Evrysdi |
| Grifols USA, LLC | $62.48 | 2023 | Gamunex-C |
| Cala Health, INC. | $59.77 | 2023-2025 | Cala Kiq, Cala Trio, Cala Kiq |
| Mdd US Operations, LLC | $50.69 | 2023-2025 | Gocovri, Gocovri |
| Livanova USA, INC. | $46.79 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $40.08 | 2022 | |
| Supernus Pharmaceuticals, INC. | $37.38 | 2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $32.21 | 2023-2024 | Nuedexta |
| Amneal Pharmaceuticals LLC | $31.09 | 2024 | Ongentys, Crexont |
| Kyowa Kirin, INC. | $30.40 | 2020 | |
| Neurocrine Biosciences, INC. | $29.12 | 2024 | Ingrezza |
| Csl Behring | $28.01 | 2025 | Hizentra |
| Lundbeck LLC | $27.52 | 2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $25.25 | 2022 | |
| Genzyme Corporation | $24.04 | 2025 | |
| Aucta Pharmaceuticals, INC. | $22.16 | 2025 | Motpoly Xr |
| Sumitomo Pharma America, INC. | $22.03 | 2024 | Aptiom |
| Tanabe Pharma America, INC. | $21.52 | 2024 | |
| Insightec,INC | $21.29 | 2023 | Exablate |
| Ani Pharmaceuticals, INC. | $18.75 | 2024 | Purified Cortrophin Gel |
| Itf Therapeutics LLC | $18.64 | 2024 | |
| Tg Therapeutics, INC. | $16.45 | 2025 | |
| Emd Serono, INC. | $15.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipali Nemade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.